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Introduction
In the recent times, early intervention strategies and advances in antiplatelet therapy have reduced the risk of recurrent coronary events and mortality in patients with acute coronary syndromes (ACS). Antiplatelet therapy has been proven of major clinical benefit in cardiovascular clinical trials and is routinely prescribed in secondary prevention. However, major bleeding is a life threatening complication of triple antiplatelet therapy, and it can increase the risk of in-hospital death by 60%. 1 Also, major bleeding episodes can adversely affect long-term prognosis by increasing the 1-year mortality and re-infarction rates by five-fold. 2 Some patient subsets are at increased risk of having a major bleed. Ticagrelor is a newer reversible P2Y12 receptor antagonist, reported to be more effective than existing antiplatelet therapies with a similar safety profile. 3 However, long-term safety data are still awaited. Here, we report a 58-year-old male who developed spontaneous acute subdural hematoma (SDH) on antiplatelet therapy with Aspirin and ticagrelor following percutaneous coronary intervention (PCI) for a cardiac event and placing a drug eluting stent.
Case report
This 58-year-old male without any previous history of ischemic heart disease was admitted to the cardiology services i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) s 3 0 -s 3 5
Six weeks on antiplatelet therapy, the patient presented with progressively increasing right hemicranial headache of 10 days duration involving the right temporoparietal and frontal region. It was of throbbing type, present throughout the day and was associated with nausea and vomiting. He had no diplopia, blurring of vision, seizures, loss of consciousness, or limb weakness. He did not complain of hematemesis, hematuria, melena or bleeding per rectum. He denied any history of head trauma. He was evaluated by the neurology team and admitted for further management.
Clinical examination revealed a conscious, irritable patient with stable hemodynamic parameters. There was no papilloedema or cranial nerve involvement. He did not have any lateralizing neurodeficits. Routine blood investigations including hemogram, coagulation parameters, liver function, and renal function tests were normal. Cardiac evaluation including electrocardiogram, transthoracic echocardiography, and cardiac biomarker levels were normal. Noncontrast computed tomography (CT scan) on head revealed a right temporoparietal acute SDH (Fig. 1) . There was no evidence of fracture or external contusion. Rest of the brain parenchyma was normal. This patient had a spontaneous acute right temporoparietal SDH.
A neurosurgical consultation was sought, and the patient was planned for conservative therapy and observation. He was monitored for progression of intracranial hematoma. As he was on antiplatelet therapy and developed an intracranial bleed, a decision was made to stop ticagrelor. He continued to receive aspirin and was added on clopidogrel, as cardiologists felt that stopping all of the antiplatelet drugs could have been too risky. He was started on analgesics, followed by short course of steroids and head end elevation. Headache reduced on day 4 of therapy, and he was discharged. Repeat CT brain on day 7 revealed a resolving hematoma as shown in Fig. 2 . He remained asymptomatic at 90-day follow-up.
Discussion
Intracranial hemorrhage (ICH) is the most feared bleeding complication known to occur in a patient on antiplatelet therapy following PCI. Here, we describe a case of spontaneous acute SDH in a patient with ischemic heart disease on antiplatelet therapy with Aspirin and Ticagrelor following PCI. He recovered with no residual neurological deficits. Timely withdrawal of ticagrelor resulted in resolution of hematoma and improvement in the patient symptoms. Early recognition of this complication with appropriate management resulted in a good outcome in this patient. Bleeding complications after antiplatelet therapy have been long recognized and well-studied in large randomized trials. They constitute a key safety end point in all clinical trials assessing newer antiplatelet drugs in ACS. 4 In clinical trials, major bleeding is reported in 1-10% of all patients on antiplatelet therapy, and it is a cause of significant morbidity and mortality. 5 The factors predisposing to increased risk of 
having a major bleed are elderly patients, female sex, low body weight, impaired renal function, base line anemia, and previous history of intracerebral haemorrhage. 6 It is interesting to note that ICH is uniformly classified as fatal/life threatening bleeding as per PLATO, 7 TIMI, 8 and GUSTO 9 trial definitions, though definition of a major bleed varies from trial-to-trial. Occurrence of ICH in turn is associated with increased risk of mortality and residual neurological deficit. Though a five-fold increase in risk of mortality/re-infarction rates at 1-year follow-up has been reported, causal link between bleeding and recurrent ischemic event is not proven. 2 Connolly et al. 10 To the treating neurophysicians, newer antiplatelet therapies throw newer challenges. They are more potent, their actions are difficult to monitor and there are no reversal agents available if needed in case of neurosurgical emergencies. Stopping these drugs in a perioperative setting may be equally hazardous on one hand; achieving hemostasis during emergency neurosurgical intracranial interventions is more difficult on the other. Though it is advantageous to have an antiplatelet medication, which does not require regular monitoring of its effect, same can sum up as a disadvantage, when the patient develops an intracranial bleed requiring neurosurgical intervention and monitoring needs priority. Hence, caution needs to be exercised in prescribing these medications to optimize the therapeutic benefits.
Conclusion
This case depicts a possible association of spontaneous acute SDH and antiplatelet therapy with aspirin and ticagrelor.
Though Ticagrelor is found to be superior to other ADP antagonists in reducing cardiovascular morbidity, it has increased risk of life threatening ICH compared to clopidogrel. Treating cardiologist must identify patient subsets with increased risk of bleeding while prescribing antiplatelet therapy and design appropriate treatment strategies to improve clinical outcome.
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